摘要
可泮利塞为一种Ⅰ型磷脂酰肌醇3-激酶抑制剂,由拜耳制药公司研发,于2017年9月获美国食品和药物管理局加速批准,用于治疗前期至少接受过两次系统治疗的复发性滤泡性淋巴瘤。推荐给药方法为疗程的第1、 8和15日给予可泮利塞60 mg, 1 h内静脉输注, 28 d为一个疗程。可泮利塞最常见不良反应包括血糖升高、腹泻、高血压、白细胞减少、下呼吸道感染及血小板减少等。
Copanlisib is a classⅠphosphatidylinositol 3-kinase inhibitor.It was developed by Bayer.In September 2017,copanlisib was approved by the U.S.Food and Drug Adiministration for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies.The recommended dosage of copanlisib is 60 mg administered as a 1-hour intravenous infusion on days 1,8,and 15 of a 28-day treatment cycle.The most common adverse reactions are hyperglycemia,diarrhea,hypertension,leukopenia,lower respiratory tract infections,thrombocytopenia,and so on.
作者
杨君义
YANG Jun-yi(Department of Pharmacy,Central Hospital of Linyi City,Linyi SHANDONG 276400,China)
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2019年第2期74-76,共3页
Chinese Journal of New Drugs and Clinical Remedies
